Cyclacel Limited Company Profile
Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200; CYC400), Penetratin®-small molecule complexes (CYC300), Pimetic™ small molecules mimicking natural cancer suppressing genes (CYC100), and intelligent delivery and targeting systems (Penetratin® and SGC™ technologies). Cyclacel’s Polgen division (Cambridge, UK) is in a world-first effort to validate, develop assays and discover drugs arising from 100 genomic targets regulating cancer mitosis. CYC202, the lead drug candidate is entering Phase I this autumn as the 3rd entry in a worldwide race involving several pharmaceutical majors.
Cyclacel’s clinical strategy for CYC202 includes several Phase I and Phase II trials in patients with solid tumors with the objective of defining the most attractive population to test the drug’s properties, as well as studying pharmacokinetics and optimal dosing. The commercialization strategy calls for positioning the company’s CDK inhibitors as modern, mechanism-based medicines with low toxicity and high target specificity to be used for treating cancer as a chronic disease. CDK inhibitors in general, and CYC202 in particular, have shown activity in animal models of non-cancerous hyperproliferative diseases such as autoimmune, cardiovascular, dermatological and inflammatory conditions.
Location
James Lindsay Place; Dundee Technopole
Dundee
Tayside
DD1 5JJ
United Kingdom
Contact
Phone: 44 1382 206 062
Fax: 44 1382 206 067
Email: srombotis@cyclacel.com
News Articles
Cyclacel sells four disputed romidepsin-related patents to Celgene
USA based Cyclacel Pharmaceuticals (Nasdaq: CYCC) says that it has entered into a definitive agreement with biotech major Celgene (Nasdaq: CELG) to sell to Celgene four Cyclacel-owned patents related...
Public offering nets $18.8mm for [Cyclacel]
[Cyclacel Pharmaceuticals Inc.] (mainly cancer therapies; also has projects for kidney disease, diabetes, and HIV/AIDS) netted $18.8mm through public offering of 6.67mm common shares at $3 each. Proce...
Public offering nets $19.3mm for [Cyclacel]
[Cyclacel Pharmaceuticals Inc.] (mainly cancer therapies; also has projects for kidney disease, diabetes, and HIV/AIDS) netted $19.3mm through the public offering of 6.8mm common shares (including the...
[Cyclacel] and [Celgene] settle patent litigation surrounding {Istodax}
Cancer drug developers [Cyclacel Pharmaceuticals Inc.] and [Celgene Corp.] have settled three-year-old patent litigation surrounding romidepsin, the main drug in Celgene’s {Istodax}, which is market...
BERKELEY HEIGHTS, N.J., April 4, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced that it has entered into a definitive agr...
Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
By Scott Matusow:Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat...
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Cyclacel Pharmaceuticals Inc. in a patent infringement action in which Cyclacel accused Celgene Corporation...
Cyclacel Heats Up On Clinical Trial Progression
By Brian L. Wilson:The market is beginning to bid for shares of Cyclacel Pharmaceuticals (CYCC), which hit a new 52-week high yesterday, Oct. 15. The 22.5% rally we saw by the closing bell was a react...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200;...
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious...
More Information about "Cyclacel Limited" on BioPortfolio
We have published hundreds of Cyclacel Limited news stories on BioPortfolio along with dozens of Cyclacel Limited Clinical Trials and PubMed Articles about Cyclacel Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cyclacel Limited Companies in our database. You can also find out about relevant Cyclacel Limited Drugs and Medications on this site too.
